Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Press Release on announcement of Buy- Back of Equity shares of the Company".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals' board has approved a buyback of up to 16 lakh equity shares at ₹250 per share through the Tender Offer route, for a total outlay of up to ₹40 crores. The buyback price represents a 40% premium over the current market price, and the size is about 2.4% of total equity and 7.3% of non-promoter holdings. Promoters will not participate, so their stake will rise from 67.2% to 68.9% post-buyback. The company had ₹176 crores in free cash as of December 31, 2025, and the buyback is expected to improve ROCE by roughly 400 basis points. The move is subject to shareholder approval.
Positive for retail shareholders — the 40% premium to market price offers a strong exit opportunity via the tender route, and reduced share count should boost EPS and ROCE. Promoter non-participation means public investors get full allocation of the tendered shares.